Syngene Extends Strategic Partnership with Bristol Myers Squibb Through 2035
Syngene International, a global contract research, development, and manufacturing organization (CRDMO), has announced the renewal and extension of its long-term strategic partnership with Bristol Myers Squibb through 2035. The enhanced agreement significantly expands the range of integrated services offered across the entire drug development value chain. These capabilities span early discovery—including chemistry, biology, and drug metabolism and pharmacokinetics—through translational research, pharmaceutical development, manufacturing, clinical trial support, and data and IT services.
This comprehensive integration is designed to support a smooth transition from early research to commercial production. The renewed collaboration represents the next stage in the relationship, further strengthening Syngene’s role as a trusted partner providing end-to-end scientific and manufacturing solutions.
Commenting on the extension, Peter Bains, Managing Director and Chief Executive Officer of Syngene International Ltd., said that the partnership with Bristol Myers Squibb, which has now exceeded 25 years, is built on strong scientific capabilities, dependable execution, and a shared vision to deliver breakthrough therapies. He noted that extending the agreement through 2035 allows both organizations to take a long-term, forward-looking approach to developing new infrastructure and capabilities over the next decade.
This long-range planning, he added, is central to the strategic value of the partnership. Syngene looks forward to continuing its support of Bristol Myers Squibb’s upcoming discovery, development, and manufacturing initiatives aimed at improving patient outcomes globally.
Payal Sheth, Senior Vice President, Therapeutic Discovery Sciences at Bristol Myers Squibb, emphasized that patient needs remain at the core of the company’s mission. She highlighted the importance of the long-standing collaboration with Syngene in helping advance Bristol Myers Squibb’s scientific goals. According to her, the expanded scope of the partnership underscores the company’s commitment to driving innovative science through closer integration of research, development, and manufacturing capabilities, ultimately accelerating the delivery of transformative therapies to patients worldwide.
The partnership between Syngene and Bristol Myers Squibb dates back to 1998 and led to the creation of the Biocon Bristol Myers Squibb Research and Development Center (BBRC), Syngene’s first dedicated R&D facility, which became fully operational in 2009. Over time, BBRC has grown into a key strategic research hub for Bristol Myers Squibb, offering integrated expertise across areas such as target identification, lead discovery and optimization, pharmaceutical development, molecular and cellular biology, protein sciences, assay development, and clinical biomarkers. Today, the center employs approximately 700 Syngene scientists who operate as an extension of Bristol Myers Squibb’s global research teams, contributing to discovery, preclinical development, and patent filings across therapeutic areas including cardiovascular disease, fibrosis, immunology, and oncology.
Since its establishment, BBRC has been instrumental in speeding the advancement of new compounds from early research through first-in-human studies, helping Bristol Myers Squibb shorten development timelines and manage overall costs more effectively.
About Syngene
Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022) is a fully integrated research, development, and manufacturing services provider supporting clients across the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemicals industries. With a workforce of more than 8,200 employees, including around 5,600 scientists, Syngene combines deep scientific expertise with strong data security practices and world-class manufacturing capabilities to accelerate innovation, reduce time-to-market, and lower development costs.
Operating more than 2.5 million square feet of specialized discovery, development, and manufacturing infrastructure across India and the United States, Syngene partners with approximately 400 global customers. These include innovative biotech firms as well as leading multinational organizations such as Bristol Myers Squibb, GSK, Zoetis, and Merck KGaA.
Click here to know more about the company’s latest Environmental, Social, and Governance (ESG) report.
Media Contacts:
Vijay Jeevanandham
Syngene International Limited
M: +91 8310914552
E: Vijay.Jeevanandham@syngeneintl.com
Alex Heeley / Abdul Khalifeh
De Facto Communications
T: +44 (0) 203 735 8165 / +44 (0) 7834784764
E: a.khalifeh@defacto.co.uk
E: a.heeley@defacto.co.uk
This comprehensive integration is designed to support a smooth transition from early research to commercial production. The renewed collaboration represents the next stage in the relationship, further strengthening Syngene’s role as a trusted partner providing end-to-end scientific and manufacturing solutions.
Commenting on the extension, Peter Bains, Managing Director and Chief Executive Officer of Syngene International Ltd., said that the partnership with Bristol Myers Squibb, which has now exceeded 25 years, is built on strong scientific capabilities, dependable execution, and a shared vision to deliver breakthrough therapies. He noted that extending the agreement through 2035 allows both organizations to take a long-term, forward-looking approach to developing new infrastructure and capabilities over the next decade.
This long-range planning, he added, is central to the strategic value of the partnership. Syngene looks forward to continuing its support of Bristol Myers Squibb’s upcoming discovery, development, and manufacturing initiatives aimed at improving patient outcomes globally.
Payal Sheth, Senior Vice President, Therapeutic Discovery Sciences at Bristol Myers Squibb, emphasized that patient needs remain at the core of the company’s mission. She highlighted the importance of the long-standing collaboration with Syngene in helping advance Bristol Myers Squibb’s scientific goals. According to her, the expanded scope of the partnership underscores the company’s commitment to driving innovative science through closer integration of research, development, and manufacturing capabilities, ultimately accelerating the delivery of transformative therapies to patients worldwide.
The partnership between Syngene and Bristol Myers Squibb dates back to 1998 and led to the creation of the Biocon Bristol Myers Squibb Research and Development Center (BBRC), Syngene’s first dedicated R&D facility, which became fully operational in 2009. Over time, BBRC has grown into a key strategic research hub for Bristol Myers Squibb, offering integrated expertise across areas such as target identification, lead discovery and optimization, pharmaceutical development, molecular and cellular biology, protein sciences, assay development, and clinical biomarkers. Today, the center employs approximately 700 Syngene scientists who operate as an extension of Bristol Myers Squibb’s global research teams, contributing to discovery, preclinical development, and patent filings across therapeutic areas including cardiovascular disease, fibrosis, immunology, and oncology.
Since its establishment, BBRC has been instrumental in speeding the advancement of new compounds from early research through first-in-human studies, helping Bristol Myers Squibb shorten development timelines and manage overall costs more effectively.
About Syngene
Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022) is a fully integrated research, development, and manufacturing services provider supporting clients across the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemicals industries. With a workforce of more than 8,200 employees, including around 5,600 scientists, Syngene combines deep scientific expertise with strong data security practices and world-class manufacturing capabilities to accelerate innovation, reduce time-to-market, and lower development costs.
Operating more than 2.5 million square feet of specialized discovery, development, and manufacturing infrastructure across India and the United States, Syngene partners with approximately 400 global customers. These include innovative biotech firms as well as leading multinational organizations such as Bristol Myers Squibb, GSK, Zoetis, and Merck KGaA.
Click here to know more about the company’s latest Environmental, Social, and Governance (ESG) report.
Media Contacts:
Vijay Jeevanandham
Syngene International Limited
M: +91 8310914552
E: Vijay.Jeevanandham@syngeneintl.com
Alex Heeley / Abdul Khalifeh
De Facto Communications
T: +44 (0) 203 735 8165 / +44 (0) 7834784764
E: a.khalifeh@defacto.co.uk
E: a.heeley@defacto.co.uk
Companies